Economic evaluation of sirolimus-eluting stents.
BACKGROUND
Sirolimus-eluting stents have recently been shown to reduce the risk of restenosis among patients who undergo percutaneous coronary intervention (PCI). Given that sirolimus-eluting stents cost about 4 times as much as conventional stents, and considering the volume of PCI procedures, the decision to use sirolimus-eluting stents has large economic implications.


METHODS
We performed an economic evaluation comparing treatment with sirolimus-eluting and conventional stents in patients undergoing PCI and in subgroups based on age and diabetes mellitus status. The probabilities of transition between clinical states and estimates of resource use and health-related quality of life were derived from the Alberta Provincial Project for Outcome Assessment in Coronary Heart Disease (APPROACH) database. Information on effectiveness was based on a meta-analysis of randomized controlled clinical trials (RCTs) comparing sirolimus-eluting and conventional stents.


RESULTS
Cost per quality-adjusted life year (QALY) gained in the baseline analysis was Can58,721 dollars. Sirolimus-eluting stents were more cost-effective in patients with diabetes and in those over 75 years of age, the costs per QALY gained being 44,135 dollars and 40,129 dollars, respectively. The results were sensitive to plausible variations in the cost of stents, the estimate of the effectiveness of sirolimus-eluting stents and the assumption that sirolimus-eluting stents would prevent the need for cardiac catheterizations in the subsequent year when no revascularization procedure was performed to treat restenosis.


CONCLUSIONS
The use of sirolimus-eluting stents is associated with a cost per QALY that is similar to or higher than that of other accepted medical forms of therapy and is associated with a significant incremental cost. Sirolimus-eluting stents are more economically attractive for patients who are at higher risk of restenosis or at a high risk of death if a second revascularization procedure were to be required.
Shrive
Fiona M
FM
Department of Community Health Sciences, University of Calgary, Calgary, Alta.
Manns
Braden J
BJ
Galbraith
P Diane
PD
Knudtson
Merril L
ML
Ghali
William A
WA
D000367:Age Factors; D000368:Aged; D015906:Angioplasty, Balloon, Coronary / Q000191:economics* / Q000401:mortality; D015331:Cohort Studies; D003327:Coronary Disease / Q000191:economics* / Q000401:mortality / Q000628:therapy; D023903:Coronary Restenosis; D003362:Cost-Benefit Analysis; D048909:Diabetes Complications; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000191:economics*; D008297:Male; D008390:Markov Chains; D008875:Middle Aged; D019057:Quality-Adjusted Life Years; D012306:Risk; D020123:Sirolimus / Q000008:administration & dosage / Q000191:economics*; D015607:Stents / Q000191:economics*
D007166:Immunosuppressive Agents; D020123:Sirolimus